| COVID-19 |
1 |
1 |
| Cardiovascular Risk Management |
0 |
0.9 |
| Artery |
0 |
0.62 |
| Atherosclerosis |
0 |
0.51 |
| Tissue |
0 |
0.39 |
| Cardiomyopathy |
0 |
0.37 |
| Influenza |
0 |
0.34 |
| Heart |
0 |
0.31 |
| Lipids Management |
0 |
0.29 |
| Biologic Therapy |
0 |
0.25 |
| Cardiovascular disease |
0 |
0.23 |
| New York |
0 |
0.23 |
| Pandemic |
0 |
0.23 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.23 |
| Acute Respiratory Distress Syndrome |
0 |
0.19 |
| Interleukin |
0 |
0.15 |
| Severe Acute Respiratory Syndrome |
0 |
0.15 |
| Viral Infection |
0 |
0.15 |
| Virology |
0 |
0.15 |
| Depression |
0 |
0.1 |
| Microbiome |
0 |
0.1 |
| Myocardial Infarction (MI) |
0 |
0.1 |
| Vaccines |
0 |
0.1 |
| Autopsy |
0 |
0.08 |
| Blood |
0 |
0.08 |
| Brain |
0 |
0.08 |
| Cytokines |
0 |
0.08 |
| Geriatrics |
0 |
0.08 |
| Infarction |
0 |
0.08 |
| Lung |
0 |
0.08 |
| Microbiology |
0 |
0.08 |
| Myocarditis |
0 |
0.08 |
| Pathogenesis |
0 |
0.08 |